Oppenheimer began coverage of Nutanix (NASDAQ:NTNX) with an Outperform rating and an $80 price target. Analyst Param Singh ...
When you buy through links on our articles, Future and its syndication partners may earn a commission.
In a report released today, Matthew Biegler from Oppenheimer maintained a Hold rating on Fate Therapeutics (FATE – Research Report). The company’s shares closed yesterday at $2.38. According to ...
(JTA) — Friday is not just “Barbie” release day — moviegoers are also planning to fill theaters across the United States to see Christopher Nolan’s “Oppenheimer” biopic. Many hope it ...
Greece’s Thessaloniki Film Festival ends this evening with a screening of The End, the latest feature project from the ...
In a report released today, Matthew Biegler from Oppenheimer maintained a Buy rating on Oric Pharmaceuticals (ORIC – Research Report), with a price target of $15.00. The company’s shares closed ...
Oppenheimer's Limited-Edition Steelbook releases November 19 and comes with 4K and standard Blu-ray discs as well as a ...
Oppenheimer has become the latest Wall Street firm to raise its year-end price target for the S&P 500. Chief Market Strategist John Stoltzfus said in a report shared with MarketWatch on Monday that ...
Oppenheimer upgrades MoneyLion to Outperform as it benefits from lower interest rates, easing regulations, and potential ...
Oppenheimer director, Christopher Nolan to return with new movie featuring Zendaya, Anne Hathaway, Tom Holland, and more ...
Backers of some sure-fire hits are hoping for the former. Denis Villeneuve’s “Dune: Part Two” has already taken in $714.4 ...